热门资讯> 正文
BridgeBio ' s的甲状腺素转淀粉样变性治疗获得欧盟批准
2025-02-11 23:58
- BridgeBio Pharma (NASDAQ:BBIO) announced that the European Commission has granted marketing authorization for acoramidis, sold under the brand name BEYONTTRA, in the European Union.
- It is approved for treating adult patients with wild-type or variant transthyretin amyloidosis with cardiomyopathy.
- The EU approval is based on the results of the pivotal ATTRibute-CM Phase 3 study, which demonstrated significant benefits for cardiovascular outcomes.
- Following this approval, Bayer plans to launch acoramidis in the first half of 2025.
- The drug is also under review by the Japanese Pharmaceuticals and Medical Devices Agency and the Brazilian Health Regulatory Agency.
- Source: Press Release
More on BridgeBio Pharma
- BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
- BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
- BridgeBio: Next Chapter Begins After Attruby Approval
- Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
- Seeking Alpha’s Quant Rating on BridgeBio Pharma
推荐文章
美股机会日报 | 金价年内或触及3800美元？国际大行集体唱多黄金！超微电脑涨超5%
一周财经日历 | 万众瞩目！9月美联储利率决议来袭；三只港股新股即将上市
能否赶上美联储下周议息会议？美参院就米兰理事提名表决时间定了
港股异动 | 重磅利好！阿里涨近7%，百度涨超6%
华盛早报 | 创近4年新高！阿里大涨8%；外资热情势不可挡！大摩：超九成美国投资者愿加仓中国资产
美股机会日报 | 美国8月CPI符合预期，初请失业金人数创近四年新高！“网红股”Opendoor股价大涨超30%
万亿南向“活水”疯狂抢筹！重仓阿里巴巴逾1200亿港元，如何抄“聪明钱”的作业？
降息预期压倒经济隐忧！调查显示：美股今年有望强势收官
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
